Skip to content

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Pfizer logo
PfizerPFE
0.1×0.0×
Amgen logo
AmgenAMGN
0.0×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
1.5×-0.6×
Tango Therapeutics logo
Tango TherapeuticsTNGX
11.2×+9.5×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s cash ratio?
Erasca, Inc. (ERAS) reported cash ratio of 1.8× in Q1 2026.
How has Erasca, Inc.'s cash ratio changed year-over-year?
Erasca, Inc.'s cash ratio decreased by 36.0% year-over-year, from 2.8× to 1.8×.
What is the long-term trend for Erasca, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Erasca, Inc.'s cash ratio has grown at a -11.5% compound annual growth rate (CAGR), from 4.8× to 2.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.